COVID-19 相关关注聚集于血小板
本文为《Blood》同期两篇研究的述评。Manne 等与 Hottz 等的研究探讨血小板在 COVID-19 相关血栓并发症中的作用,提示血小板过度活跃参与 COVID-19 相关凝血病;COVID-19 相关凝血病以 D-二聚体升高、轻度血小板减少和活化部分凝血活酶时间延长为特征,患者血栓发生率增加。
要点
- COVID-19 相关凝血病表现为 D-二聚体升高、轻度血小板减少和活化部分凝血活酶时间延长。
- COVID-19 患者血栓发生率增加。
- 两篇研究提示血小板过度活跃参与 COVID-19 相关凝血病。
核心结论
- Manne 等与 Hottz 等的研究确立血小板过度活跃参与 COVID-19 相关凝血病。
研究设计与样本
- 本文为《Blood》同期两篇研究(Manne 等与 Hottz 等)的述评。
主要发现
- COVID-19 相关凝血病以 D-二聚体升高、轻度血小板减少和活化部分凝血活酶时间延长为特征。
- COVID-19 患者血栓发生率增加。
- 两篇研究探讨血小板在 COVID-19 血栓并发症中的作用,提示血小板过度活跃参与该凝血病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this issue of Blood, articles by Manne et al and Hottz et al highlight platelet hyperactivity in COVID-19–associated pathophysiology., Although the hallmarks of COVID-19 include a brisk inflammatory response and respiratory symptoms, the hematologic manifestations of this infection have also garnered attention, with thrombotic complications taking center stage., COVID-19–associated coagulopathy has been characterized by an elevated D-dimer, mild thrombocytopenia, and a prolongation of the activated partial thromboplastin time. Alongside these laboratory abnormalities, patients present with increased rates of thrombosis. The role of platelets in the thrombotic complications of COVID-19 is explored in these 2 articles, establishing that platelet hyperactivity contributes to the coagulopathy seen in COVID-19.
引用
- Battinelli EM. COVID-19 concerns aggregate around platelets. Blood. 2020. PMID: 32957116. doi:10.1182/blood.2020007805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。